ArticleThe Journal of clinical investigation2022
Tumor Treating Fields: killing two birds with one stone.
Article in The Journal of clinical investigation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 16 citations in OpenAlex.
- Microstructural MRI combined with metabolic MRI to evaluate the progression-free survival of patients with glioblastoma at the early follow-up after tumor treating fields: a pilot study.BMC medical imaging · 2026Article
- Tumor treating fields in malignant pleural mesothelioma: from cytoskeletal collapse to immunophenotypic conversion.Frontiers in immunology · 2026Review
- Electricity-Based Locoregional Cancer Therapies and Their Associated Drug Delivery Technologies: From Principles of Action to Clinical Implications.Biomaterials research · 2026Review
- Modulating the glioma microenvironment with laser interstitial thermal therapy: mechanisms and therapeutic implications.Journal of neuro-oncology · 2025Review
- Advancement in tumor treating fields of mechanism, clinical applications, and future directions.Discover oncology · 2025Review
- Alternating electric fields transform the intricate network of tumour vasculature into orderly parallel capillaries and enhance the anti-angiogenesis effect of bevacizumab.Cell proliferation · 2025Article
- Advanced tumor electric fields therapy: A review of innovative research and development and prospect of application in glioblastoma.CNS neuroscience & therapeutics · 2024Review
- Targeting ferroptosis opens new avenues in gliomas.International journal of biological sciences · 2024Review
- Review
- Targeting cGAS/STING signaling-mediated myeloid immune cell dysfunction in TIME.Journal of biomedical science · 2023Review
- Therapeutic potential of tumor treating fields for malignant brain tumors.Cancer reports (Hoboken, N.J.) · 2023Review
- Positioning Transclival Tumor-Treating Fields for the Treatment of Diffuse Intrinsic Pontine Gliomas.Life (Basel, Switzerland) · 2023Article
- Comprehensive Analysis Identified Glycosyltransferase Signature to Predict Glioma Prognosis and TAM Phenotype.BioMed research international · 2023Article
- The schemes, mechanisms and molecular pathway changes of Tumor Treating Fields (TTFields) alone or in combination with radiotherapy and chemotherapy.Cell death discovery · 2022Review
Corrections and comments
- Comment on
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Given its aggressive natural history and immunosuppressive nature, glioblastoma (GBM) remains difficult to treat. Tumor Treating Fields (TTFields) are a promising treatment for GBM patients, yet the entirety of their antitumor action has not been fully elucidated. In a recent issue of the JCI, Chen et al. explored the effect of TTFields in reinvigorating immune responses. By elegant step-by-step approaches, the authors demonstrated that TTFields promote the production of immune-stimulating proinflammatory and interferon type 1 cytokines in tumor cells in a cGAS/STING- and AIM2 inflammasome-dependent mechanism, thereby activating the immune system. The findings show that TTFields not only directly inhibit tumor cell growth, as previously reported, but enhance antitumor immunity, suggesting TTFields can be used as an immune-modulating approach in GBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.